<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753712</url>
  </required_header>
  <id_info>
    <org_study_id>KFL3502</org_study_id>
    <secondary_id>2015-000801-38</secondary_id>
    <nct_id>NCT02753712</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma</brief_title>
  <official_title>A Two-arm, Randomised, Assessor-blind, Parallel Group Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) and Relvar® Ellipta® DPI on Ventilation Heterogeneity in Subjects With Partially Controlled or Uncontrolled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate improvement of peripheral airway resistance&#xD;
      (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">August 14, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring peripheral airway resistance (R5-R20)</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>Measuring peripheral airway resistance (R5-R20)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure ventilation heterogeneity (using Functional Respiratory Imaging)</measure>
    <time_frame>From baseline to week 9</time_frame>
    <description>measures of ventilation heterogeneity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring distal airway volume and resistance (using impulse oscillometry)</measure>
    <time_frame>From baseline to week 8 and 9</time_frame>
    <description>Measuring distal airway volume and resistance (using Functional Respiratory Imaging (FRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate asthma control (using ACQ-6) )</measure>
    <time_frame>From baseline to week 4 and 8</time_frame>
    <description>Evaluate asthma control (using ACQ-6) )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate health status (using AQLQ)</measure>
    <time_frame>From baseline to week 4 and 8</time_frame>
    <description>Evaluate health status (using AQLQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>fluticasone/vilanterol DPI (Relvar Ellipta DPI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalation powder. 92/22µg, I inhalation od</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone/formoterol BAI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pressurised suspension for inhalation 125/5µg, 2 inhalations bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Formoterol BAI</intervention_name>
    <arm_group_label>Fluticasone/formoterol BAI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)</intervention_name>
    <arm_group_label>fluticasone/vilanterol DPI (Relvar Ellipta DPI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects on Seretide Accuhaler 250/50 µg at screening:&#xD;
&#xD;
          1. Male and female subjects ≥18 years old.&#xD;
&#xD;
          2. Adequate contraception&#xD;
&#xD;
          3. Documented clinical history of asthma for ≥6 months prior to screening visit&#xD;
&#xD;
          4. Using Seretide Accuhaler at a stable dose of 250/50 μg BID at screening for ≥ 8 weeks.&#xD;
&#xD;
          5. uncontrolled asthma as defined by Asthma Control Questionnaire (ACQ-6) score ≥ 1.0&#xD;
&#xD;
          6. R5-R20 ≥ 0.10 kPa/L/s as measured on impulse oscillometry during the screening visit.&#xD;
&#xD;
          7. Historical evidence (within 24 months) of eosinophilic airways disease evidenced by&#xD;
             sputum eosinophil count ≥ 3% and/or FeNO 35 ppb.&#xD;
&#xD;
        Inclusion criteria for subjects on equivalent /higher dose or other ICS-LABAs or higher&#xD;
        dose of Seretide at screening:&#xD;
&#xD;
          1. Male and female subjects ≥18 years old.&#xD;
&#xD;
          2. Adequate contraception&#xD;
&#xD;
          3. Documented clinical history of asthma for ≥6 months prior to screening visit&#xD;
&#xD;
          4. R5-R20 ≥0.07 kPa/L/s as measured on impulse oscillometry during the screening visit.&#xD;
&#xD;
               -  5. Historical evidence (within past 24 months) of eosinophilic airways disease,&#xD;
                  evidenced by sputum eosinophil count ≥3% and/or FeNo ≥35 ppb.&#xD;
&#xD;
        Exclusion Criteria for all subjects:&#xD;
&#xD;
          1. Any severe chronic respiratory disease other than asthma.&#xD;
&#xD;
          2. Subject has a smoking history ≥10 &quot;pack years&quot; (i.e., at least 1 pack of 20&#xD;
             cigarettes/day for 10 years or 10 packs/day for 1 year, etc.)&#xD;
&#xD;
          3. Current smoking history within 12 months prior to the screening visit&#xD;
&#xD;
          4. Near fatal or life-threatening (including intubation) asthma within the past year.&#xD;
&#xD;
          5. Known history of systemic (injectable or oral) corticosteroid medication within 1&#xD;
             month of visit 1.&#xD;
&#xD;
          6. Evidence of a clinically unstable disease as determined by medical history or physical&#xD;
             examination that, in the investigator's opinion, precludes entry into the study.&#xD;
             'Clinically unstable' is defined as any disease that, in the opinion of the&#xD;
             Investigator, would put the subject at risk through study participation, or which&#xD;
             would affect the outcome of the study.&#xD;
&#xD;
          7. In the investigator's opinion a clinically significant upper or lower respiratory&#xD;
             infection within 4 weeks prior to visit 1.&#xD;
&#xD;
          8. Current evidence or known history of alcohol and/or substance abuse within 12 months&#xD;
             prior to the screening visit.&#xD;
&#xD;
          9. Subject has taken β-blocking agents, tricyclic antidepressants, monoamine oxidase&#xD;
             inhibitors, astemizole, quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors&#xD;
             such as ketoconazole within 1 week prior to screening visit.&#xD;
&#xD;
         10. Current use of bronchodilators / anti-inflammatory agents other than those specified&#xD;
             in the protocol.&#xD;
&#xD;
         11. Known or suspected sensitivity to study drug or excipients.&#xD;
&#xD;
         12. Participation in a clinical drug study within 30 days of the screening visit.&#xD;
&#xD;
         13. Current participation in a clinical study.&#xD;
&#xD;
        Exclusion Criteria for subset of subjects undergoing OR-MRI and HD-CT&#xD;
&#xD;
          1. Contraindication for MRI scanning (as assessed by local MRI safety questionnaire),&#xD;
             which includes, but is not limited to: presence of non-MRI compatible artificial heart&#xD;
             valves, hydrocephalus shunts, intracranial aneurysm clips, joint replacements or metal&#xD;
             implants, pacemakers or other cardiac rhythm management devices, claustrophobia,&#xD;
             history of metal in the eye, presence of shrapnel from a war injury, callipers or&#xD;
             braces, dentures, dental plates or hearing aids that include metal and cannot be&#xD;
             removed, history of epilepsy or black-outs, ear implants, piercings cannot be removed,&#xD;
             intrauterine contraceptive device or coil.&#xD;
&#xD;
          2. Inability to stay in the supine position for the duration of the scanning procedure&#xD;
&#xD;
          3. Obesity (body weight &gt;140kg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Woolcock Institute of Medical Research</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>NSW 2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth Eastern Medical Centre</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy immunology and Respiratory medicine, The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The New Zealand Respiratory and Sleep Institute</name>
      <address>
        <city>Greenlane</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otago Respiratory Research Unit</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSPIRO, s.r.o. Ambulancia pneumológie a ftizeológie</name>
      <address>
        <city>Humenné</city>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DAMIZA, s.r.o. Ambulancia pneumológie a ftizeológie</name>
      <address>
        <city>Námestovo</city>
        <zip>029 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika ADUS, Pľúcna ambulancia</name>
      <address>
        <city>Poprad</city>
        <zip>05801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PULMO, s.r.o</name>
      <address>
        <city>Prešov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pľúcna ambulancia Hrebenár, s.r.o.</name>
      <address>
        <city>Spišská Nová Ves</city>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ANA JJ, s.r.o, Ambulancia klinickej imunológie a alergológie</name>
      <address>
        <city>Topoľčany</city>
        <zip>955 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Biomedical Research Unit, Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospital</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=KFL3502</url>
    <description>Link to Eu CT Register</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small airway disease</keyword>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

